---
author: Norges Bank Investment Management
date: '2025-05-04'
guest: ''
layout: post.njk
source: https://www.youtube.com/watch?v=LVxVd5P_60U
speaker: Norges Bank Investment Management
tags:
  - pharmaceutical-innovation
  - chronic-diseases
  - healthcare-systems
  - protein-engineering
  - shareholder-value
title: 诺和诺德CEO：创新是战胜慢性病、实现股东回报的关键
summary: 诺和诺德CEO Lars Fruergaard Jørgensen在投资会议上分享了公司在制药领域的创新策略。他强调通过明确的使命（战胜严重慢性病）和核心能力（蛋白质工程）来满足未被满足的社会需求。Jørgensen以GLP-1分子和每周注射胰岛素的开发为例，阐述了创新如何推动公司发展，同时为患者和社会带来巨大价值，并最终实现可观的股东回报。他指出，在服务患者和社会的同时，创新与股东价值之间存在明确的联系。
insight: ''
draft: true
series: ''
category: business
area: market-analysis
project:
  - investment-strategy
  - systems-thinking
people:
  - Lars Fruergaard Jørgensen
companies_orgs:
  - Novo Nordisk
  - Norges Bank Investment Management
products_models:
  - GLP-1
  - Insulin
  - Amylin
media_books: []
status: evergreen
---
### 创新：伟大公司与社会贡献的核心

非常感谢您的热情介绍，也感谢今天能有这个机会来到这里。这对我来说是莫大的荣幸。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Thank you very much for that kind introduction and also thank you for the opportunity to be here today. It's a great honor.</p>
</details>

我们正在讨论是什么造就了伟大的公司。显然，大家都会认为股东回报是其中之一。而我则认为，对社会的贡献是另一个重要因素。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We're talking about what makes great companies. Obviously you would all feel that return to shareholders is one. I would claim contribution to society is another.</p>
</details>

对于像**诺和诺德**（Novo Nordisk: 一家全球领先的丹麦制药公司，专注于糖尿病和肥胖症治疗）这样的公司以及所有制药公司而言，这都与创新紧密相连，而这正是今天我演讲的主题。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And for company like Nor Nordisk and all pharmaceutical companies that is linked to innovation and that's what will be the topic of my speech today.</p>
</details>

我们通常会从一个快照来评估一家公司，但就我们行业的创新而言，这些实际上是需要10年、20年、30年才能完成的旅程。正如之前提到的，我的演讲将基于我在诺和诺德30多年的经验。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We typically look at companies at a snapshot and assess a company but when it comes to innovation in our sector these are actually journeys that takes 10 20 30 years and as was mentioned my speech will be built on the more than 30 years of experience I have from Nordisk.</p>
</details>

我将首先谈谈在创新战略方面可以做出的一些选择。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I'll start by talking a bit to what are some of the choice you can make when it comes to innovation strategy.</p>
</details>

然后，我将深入探讨我们的核心优势，并举例说明我们如何在一些实际的创新项目中应用这些优势。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I'll deep strength and then give a few examples of how we have apped that in some real innovation programs.</p>
</details>

### 创新战略：明确的使命与核心能力

首先从创新战略开始。对我而言，创新战略与拥有明确的使命、抓住机会解决社会中真正未被满足的需求紧密相关。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So starting first on the innovation strategy. For me that's linked to having a clear purpose an opportunity to address some real unmid need in society.</p>
</details>

然后，你必须弄清楚如何实现这个使命。在诺和诺德，我们非常注重做出一些选择性的决定，专注于某些核心能力，在这些能力领域中，我们发展出独特的优势，目标是成为世界上该狭窄领域内最好或少数几家最好的公司之一。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then you have to figure out how do you address that purpose. And at Norisk we are very keen on making some selective choice about some core capabilities where we where we develop distinct capabilities with the eye to be the best or among the say few best companies in the world within that narrow area.</p>
</details>

所以，如果我首先阐述使命，诺和诺德的使命是“推动变革，战胜严重的**慢性病**（Chronic Diseases: 持续时间长、进展缓慢的疾病，如糖尿病、心脏病）”。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So if I unfold purpose first the purpose of Nordisk is to drive change to defeat serious chronic diseases.</p>
</details>

这里既有“慢性病”的部分，也有“推动变革”的部分。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So there's a chronic disease part and there's a drive change part.</p>
</details>

### 应对慢性病：医疗系统面临的挑战

如果你看看今天的医疗系统，它们通常是为**急性护理**（Acute Care: 针对短期、严重疾病或伤害的医疗服务）而设计的。我通常说，进入医疗系统的最佳方式是乘坐救护车，周围闪烁着很多灯光，因为那样整个系统会立即以非常有效的方式启动。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">If you look at healthcare systems today, they are typically designed for acute care. I typically say that the best way to enter the healthcare system is to arrive in an ambulance with, you know, a lot of lights around you because then the whole system gets in effect in a very effective way right away.</p>
</details>

所以，这就是我们设计医疗保健的方式。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So that's how we designed healthc.</p>
</details>

今天的现实是，医疗系统的大部分负担来自慢性病，例如患有糖尿病、**心血管疾病**（Cardiovascular Disease: 影响心脏和血管的疾病）、肥胖症等的人群。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The reality today is that most burdens to the healthcare system come from chronic diseases, people living with diabetes, cardovasc disease, obesity etc.</p>
</details>

这些是复杂的疾病，在治疗方面涉及多学科，而现有系统并非为此而设计。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And these are complex diseases multidisciplinary in terms of how they are treated and the systems are not designed for that.</p>
</details>

因此，在大多数国家，慢性病现状实际上正在危及医疗系统的长期可持续性，而这正是我们试图解决的精确使命。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So in most countries the state of chronic disease is actually jeodizing the longevity of healthc systems and that is the exact purpose that we are trying to address.</p>
</details>

我们的目标是减轻医疗系统的负担，当然，也要增强个体公民的健康韧性。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">To take the burden of the healthc system and of course strength the health resilient for the individual citizens.</p>
</details>

我们也非常重视“推动变革”。显然，我们最大的贡献是我们所做的创新，但我们也专注于预防我们所服务的疾病。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The driving chains we also take very seriously. Obviously our largest contribution is the innovation we make, but we also focused on preventing the diseases we serve.</p>
</details>

因此，我们如何组织大城市，以预防二型糖尿病，预防肥胖症，从而为医疗系统创造能力，使其能够支付我们研发出的产品？
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So how can we organize large cities in a way where we prevent type two diabetes, we prevent obesity to create capacity in the healthc system to actually pay for the products we come up with.</p>
</details>

如果今天的系统在这方面面临挑战，那么预防与提出创新同样重要。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And if the system is challenged in doing that today, prevention is as important as coming up with innovation.</p>
</details>

### 核心能力：蛋白质工程与战略创新图谱

那是我们的使命，现在转向核心能力。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So that was our purpose turning to core capabilities.</p>
</details>

我们在创新方面有过痛苦的经验，这告诉我们，当我们真正明确选择坚守我们的核心能力时，我们成功的可能性更大，而不是当我们被最新、最伟大的创新所诱惑，去追逐我们不太了解的疾病领域的新技术时。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We have painful experience in innovation that has t us that when we actually make the clear choice stay within our core capabilities we are more likely to succeed than when we attempted by the latest and the greatest innovation and chase some new technology in a disease area. We do not understand that well.</p>
</details>

因此，多年来，我们一直专注于在我们所处的领域中研究分子，并构建领先的技术来做到这一点。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So over the years we have focused a lot on working with the molecules in the areas we are in and building leading technologies to do that.</p>
</details>

因此，在**蛋白质工程**（Protein Engineering: 通过改变蛋白质的氨基酸序列来改善其功能或创造新蛋白质的技术）方面，无论是改造**胰岛素**（Insulin: 一种由胰腺产生的激素，用于调节血糖水平）分子、**GLP-1**（Glucagon-like peptide-1: 胰高血糖素样肽-1，一种天然激素，在血糖调节中发挥作用）分子还是其他大型生物分子，并能够对其进行修饰以改善其药学益处，我们都处于领先地位。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So when it comes to to protein engineering, taking an insulin molecule, taking a GLP1 molecule or another large biological molecule being able to modify that to improve the pharmaceutical benefits of that we are among the leading companies in doing that.</p>
</details>

所以，我们有一个非常简单的战略创新图谱，其中一个轴是技术。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So we have a very simple strategic innovation grid where on one axis we have technologies.</p>
</details>

我们精通少数几项技术，然后我们将这些技术应用于少数几种疾病，例如糖尿病。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So a select few technologies we master really really well and then we apply those up against a few set of diseases diabetes you know aye commitment.</p>
</details>

然后，基于邻近性思维，我们进入了肥胖症、心血管疾病以及与整个**心血管代谢疾病**（Cardiometabolic Diseases: 一组相互关联的疾病，包括糖尿病、心脏病、中风和肥胖症）领域相关的其他一些疾病。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then we have based on adjacency thinking gone into obesity card vasc disease and a few other diseases that are linked to that whole cardiometabolic space.</p>
</details>

在一些我们拥有独特能力的罕见疾病领域，情况也是如此。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And you can say the same in a few rare diseases where we also had unique capabilities.</p>
</details>

因此，这是一个非常紧密的战略创新图谱，我们可以在其中建立优势，它实际上也带来了我们整个价值链的协同效应，这些能力可以在整个价值链中产生协同作用。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So a very tight strategic innovation map where we can build strength and it actually also leads to synergies across our value chain where those capabilities lend itself for synergy across that value chain.</p>
</details>

现在，这听起来可能有点过于严格，基于戴维的评论，我也会引入文化因素，因为我们确实允许一些实验。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Now that sounds maybe a bit tight and based on Davis comment I will also bring in culture because we do allow for a bit of say experimentation.</p>
</details>

我必须承认，虽然这个图谱在指导我们的研究人员方面非常出色，但大多数产品背后实际上都有一个固执的研究人员，他们决定在过程中打破一些规则。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And I have to admit that while this grid is really good at guiding our researchers behind most products there's actually a very stub researcher that that decided to break some of the rules on the way.</p>
</details>

他们有点违背了管理层的想法，如果你想想我们整个GLP-1的探索，我稍后会详细谈谈，那是在胰岛素成功七年之后才出现的。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">To a bit go against what management thought was the right thing to do and if you Think about our whole GLP one venture which I'll talk a bit about in in a minute that came after seven years of success in insulin.</p>
</details>

所以你可以想象，当有人建议我们关注其他事物时，大多数管理层可能觉得那不是一个好主意。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So you can imagine when somebody suggested let's focus on something else most of management felt maybe that was not a good idea.</p>
</details>

然而，我想说的是，它仍然是朝着相同的使命，相同的未被满足的需求努力，并且利用了相同的核心能力。所以，我不得不说，这实际上是符合战略的。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I would say however that it was driving against the same purpose the same unmmet need and it was leveraging the same set of core capabilities. So it was actually on strategy I have to say.</p>
</details>

### GLP-1的旅程：从糖尿病到肥胖症及更广阔的领域

那么，现在离开创新战略，转向一些例子。我已经从GLP-1（胰高血糖素样肽-1）开始讲了。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So leaving a bit innovation strategy and then going to some of the examples. I already started on GLP1 glucogon like peptide one.</p>
</details>

这是目前诺和诺德强劲增长背后的分子。我们每个人体内都有这种天然激素。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">This is the molecule behind say the strong growth of Noris right now. It's a natural hormone that all of us have in our body right now.</p>
</details>

它有助于调节你午餐后的血糖水平。它还有许多其他额外益处，这使其成为解决许多心血管代谢疾病的最大机会之一。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It helps regulate your glucose level after lunch. It also has a lot of other additional benefits which creates it creates one of the biggest opportunities in terms of addressing many of these cardiometabolic diseases.</p>
</details>

如果你提取体内天然的GLP-1并想将其用作药物，它不起作用，因为它只能持续很短的时间。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The natural G1 you have in your body if you extracted that and want to use a medicine it doesn't work because it only lasts for very very short time.</p>
</details>

所以我们的身体被设计成持续产生它。因此，从研究角度来看，它不能作为药物使用，因为如果你以某种方式服用它，它只能持续几秒钟。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So our bodies are designed to produce it all the time. So from a research point of view, it doesn't work as a medicine because if you take it somehow it would last only for a few seconds.</p>
</details>

这就是我们的核心能力发挥作用的地方。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So that's where our core capabilities came in.</p>
</details>

因此，**蛋白质工程**首先对其进行修饰，使其能够持续一天，这样你就可以进行每日注射，然后继续创新游戏，使其能够每周注射一次。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So the protein engineering modifying first to make it last for one day so you can make it a daily injection and then continue the innovation game to make it a once weekly.</p>
</details>

所以，每周注射一次，甚至具有改进的药学益处和安全性益处，并且还在寻求将其制成片剂，这在教科书的观点看来是不可能的。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So a weekly injection with even improved pharmaceutical benefits and also safety benefits and also the quest to make it a tablet which was from a textbook point of view impossible.</p>
</details>

如果你问任何科学家，如果你将蛋白质制成片剂，放入胃中，它会被吸收到血液中吗？
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So if you ask any scientist if you take a protein formulate it into a tablet put it in the stomach will that be absorbed into the bloodstream?</p>
</details>

人们会说不，因为你胃里的**酶**（Enzymes: 生物体内催化生化反应的蛋白质）会分解你刚刚吃下的牛排，也会杀死这种片剂，因为它是一种蛋白质，酶会杀死它。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">People say no because the enzymes in your stomach that just broke down the steak you had will also kill this tablet because it's a protein and enimes will kill it.</p>
</details>

所以，我们的核心能力如何发挥作用的一个例子是，你如何利用它，如何通过与一家生物技术公司合作，创造一个局部**pH环境**（pH Environment: 衡量溶液酸碱度的指标），从而真正抵御酶的侵蚀，从而使GLP-1有时间释放，穿过膜进入血液。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So an example of how our core cabilities come into play is what you then do with that how can you actually make a unique formulation together with a partnership with a biotech company that creates a local pH environment that actually you know fenders off the enzymes. So there's time for the Gilp one to be released, go through the membrane and into the bloodstream.</p>
</details>

所以，那是一场重大革命，现在它已在二型糖尿病市场上市，我们已将其提交给美国审批用于肥胖症。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So that was a major revolution and that is now in the market for type two diabetes and we have submitted it for approval in obesity in the US.</p>
</details>

GLP-1的旅程始于糖尿病，我们发现它也能减轻体重。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So the Gilbon journey started in in diabetes we saw that you also lose weight.</p>
</details>

我们当时担心是否要追求肥胖症适应症，因为那时肥胖症药物的开发是一个失败干预措施的“坟场”。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We were worried about actually pursuing the obesity indication because back then development of medicines for obesity was a graveyard of failed interventions.</p>
</details>

有些产品甚至被证明是危险的，并被撤出市场。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Some of the products even turned out to be dangerous and were taken off the market.</p>
</details>

所以，我们在二型糖尿病方面抱有巨大的希望，但我们也看到患者体重减轻了。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So we had this fantastic hope in type two diabetes but we saw that patients also lost weight.</p>
</details>

因此，我们觉得我们实际上必须研究这一点，这实际上是一个出于对患者的尊重而做出的决定。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So we felt we actually had to study that and was actually a bit say decision made from say a respect for patients.</p>
</details>

因为如果观察到体重减轻，我们知道它会被用于减肥，所以我们必须研究它以展示其安全性。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Because if if there was a weight loss observed we knew that it would be used for weight loss so we had to study it to show what was actually the safety of that.</p>
</details>

所以，这实际上是为了支持患者安全而承担的风险，然后我认为，正如我们所知，它变成了一个巨大的商业机会。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So it was actually a risk taken to support patient safety and then I think as we all know it turns into a fantastic commercial opportunity.</p>
</details>

它是一种有效的减肥剂，并且后来也被证明可以降低心血管疾病、肾脏疾病、肝脏疾病的风险。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Att weight loss agent and down the road also shown that it reduces risk cut vascular disease, kidney disease, liver disease.</p>
</details>

今年晚些时候，我们将获得其在**阿尔茨海默病**（Alzheimer's Disease: 一种进行性神经退行性疾病，导致记忆力、思维和行为问题）潜在用途的数据。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And later this year will have data on potential use in Alzheimer's disease.</p>
</details>

因此，GLP-1的持续创新之旅仍在继续。我们有更多伟大的想法，现在我们还将其与其他生物制剂结合。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So the quest to continue invasion in Gilb one continues. We have more great ideas and we also now combining it with other biologies.</p>
</details>

我们非常看好**胰淀素**（Amylin: 一种与胰岛素共同分泌的激素，有助于调节血糖和饱腹感）这种生物制剂，我们认为它与GLP-1互补，并且我们正在进行后期临床试验，所以这个旅程仍在继续。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Biology we believe lot is is amin so we believe it's complementary to gp1 and we have late state clinical trials going on there so the journey continues.</p>
</details>

### 每周注射胰岛素：减轻患者负担的突破

另一个展示核心能力和使命如何发挥作用的例子是每周注射胰岛素。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Another example of how the core capabilities and the purpose comes into play is weekly insulin.</p>
</details>

正如我们所知，诺和诺德在生产胰岛素方面有着悠久的历史。当你患有1型糖尿病或2型糖尿病时，你需要定期注射胰岛素。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So nog nye history of making insulins as we all know and when you live with type one diabetes or type two diabetes you need to inject insulins on a regular basis.</p>
</details>

你的身体不再产生胰岛素或产生的胰岛素不足，这通常每天发生一次或多次，这显然给患者带来了巨大的负担，因为你必须将其与持续的血糖监测结合起来。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Longer produce insulin no longer produce enough insulin and that takes place once a day or several times a day and obviously it's a big burden for for the patients because you have to combine that with constant glucose monitoring.</p>
</details>

那么，是否有可能制造出一种每周注射一次的胰岛素，从而减轻这些日常治疗的负担呢？
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So would it be possible to make a weekly insulin that would take the burden away from these daily treatments?</p>
</details>

再次，我们合作的大多数关键意见领袖和临床医生都说那是不可能的，因为谁会愿意注射一种持续一周的胰岛素呢？那很危险，你的血糖水平可能会过低，甚至可能致死。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And again most of the key opinion leaders the clinicians we work with say that's impossible because who would like to inject insulin that stays for week because that's dangerous you can get too low glucose level, it can kill you.</p>
</details>

所以我们说，好吧，让我们再次尝试改造这种胰岛素分子。我们如何利用我们的蛋白质工程能力呢？
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh, so we said, well, let's again work a bit with this insulin molecule. How can we leverage our protein engineering capabilities?</p>
</details>

我们实际上做到了。我们现在正在推出世界上第一款每周注射一次的胰岛素，患有二型糖尿病的人可以将注射次数从365次减少到52次。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And we actually made it. We are now launching the first the world's first weekly insulin where people with type two diabetes goes from 365 injections to 52.</p>
</details>

我们证明它能很好地调节血糖水平，甚至具有非常有吸引力的安全性。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We proved that it regulates glucose level as well as st injections and even at a very attractive safety profile.</p>
</details>

所以，当你有一个明确的使命，即服务于一群有未被满足需求的特定患者，并且你在一个狭窄领域拥有世界上最深厚的能力时，许多这些“不可能”的事情都可以被克服，打破传统的障碍。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So there are many of these impossibles that when you have a strong purpose in terms of serving a defined set of of patients with the unmit needs and you have the deepest capability in the world in a narrow field you can overcome conventional barriers.</p>
</details>

### 葡萄糖敏感胰岛素：未来的探索

胰岛素的下一个探索实际上是开发一种葡萄糖敏感胰岛素。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The next quest when it comes to insulin is actually developing a glucose sensitive insulin.</p>
</details>

当你患有糖尿病时，如果能注射一种实际上对葡萄糖敏感的胰岛素，那不是太棒了吗？
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">When you live with diabetes, wouldn't it be fantastic to get a insulin injected that's actually glucose sensitive?</p>
</details>

这样当你进食时，它会启动，降低血糖水平，当血糖水平下降时，它就会关闭。这是一种智能胰岛素。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So when you eat it will switch on, bring the glucose level down and when it's brought down it switches off. So a smart insulin.</p>
</details>

有家长给我写信。我认识一位特别的家长，他已经因为一种非常非常难以控制的1型糖尿病失去了一个孩子。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Parents writing to me. I have a particular parent who already lost one child because of a very very difficult to control type one diabetes.</p>
</details>

他对我们这种药物的临床开发非常非常感兴趣，因为他还有另一个患有1型糖尿病的孩子。
<details>
<summary>View/Hide Original English</p>
</details>

所以，任何缓冲效应对于这些患者来说都非常重要。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And he is really really interested in our clinical development of this because he has another child with type one diabetes. So any buffering effect can be very important for these patients.</p>
</details>

我们已经证明我们可以让开关起作用，即当血糖水平高时，它开始释放胰岛素，当血糖水平下降时，它停止释放胰岛素。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We have proven that we can make the switch work so it start releasing insulin and it stops releasing insulin when the glucose level is high.</p>
</details>

它目前寿命仍然太短，无法作为药物使用，但回顾我之前提到的GLP-1的例子，我们最终解决了这个问题。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It's still too shortlift to be a drug but going back to the first example I gave with GP1 we we solved that down the road.</p>
</details>

所以，当我谈到它时，我开始变得激动，因为这对这些患者来说是非常感人的。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I start blossoming when I talk about it because this is very emotional for these patients.</p>
</details>

### 结论：创新、使命与股东回报的联系

所以我希望我已经阐明了创新对我们行业的重要性。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So I hope I have made the point that innovation is essential for our industry.</p>
</details>

我在七年半前担任首席执行官，在此任期内，我见证了肥胖症市场的兴起。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh, I took as CEO 7 and a half years ago and during this tenure I've seen the advent of obesity marking market opening up.</p>
</details>

作为几乎唯一的公司，我们的股价翻了八倍，然后略有回落，但自上任以来仍上涨了三倍。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Uh being the only company more less our share price eight doubling and then coming a bit down it's still a three times up since I since I took over.</p>
</details>

所以，创新与股东回报之间显然存在联系。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">So clearly there's link between innovation and shareholder return.</p>
</details>

我希望我也阐明了通过明确的使命指导，解决患者和社会的未被满足的需求，你比其他人更有可能成功。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I hope I also made the point that by having guidance by clear purpose addressing unmade need for patient and society compared to others you have a better likelihood of success than others.</p>
</details>

通过这一点，我坚信诺和诺德在未来也将是一家成功的公司，并有望成为未来最好的公司之一。非常感谢您的聆听。
<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And by saying to to that I'm quite convinced that will be a successful company for the future also and hopefully be one of the best companies for the future. Thank you very much for listening.</p>
</details>